FDA Adds Transparency On Paragraph IVs In Bid To Spur Competition

 
• By Aidan Fry
  
Generate a summary of this article
Listen to this article
Beta

By disclosing when the first paragraph IV patent challenges were filed, how many players are in the race, and whether it has decided on eligibility for 180-day exclusivity, the FDA is aiming to spur greater competition in the US generics arena.

Jellyfish
The FDA is offering greater transparency on pargraph IV patent challenges is a bid to spur greater generic competition • Source: Shutterstock

Decisions on 180-day generic market exclusivity, the number of potential first applicants qualifying for such exclusivity, the date of approval for the first applicant or applicants, the date of first commercial marketing, and the expiration date of last qualifying patent will henceforth all be added to the database of paragraph IV patent certifications published by the US Food and Drug Administration.

Acting FDA commissioner Ned Sharpless said the improvements to “one of the agency’s most viewed databases for industry” would “improve...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Generics

  • Amneal Kicks Off China Business With First Approval

    Amneal has marked its entry into China after receiving its first product approval in the market. Meanwhile, the firm has also outlined US approvals for two generics currently suffering from shortages.

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

    After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.

  • Nichi-Iko Warns Over Delays From Toyama Plant

    Nichi-Iko says that remediation activities at its Toyama plant in the wake of a suspension over GMP violations mean that there may be delays to supply.

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.